New options for the management of chronic hyperkalemia

Linda Fried¹, Csaba P. Kovesdy² and Biff F. Palmer³

¹Medicine, Epidemiology, and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ²Clinical Outcomes and Clinical Trials Program in Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; and ³Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.

Kidney International Supplements (2017) 7, 164–170; https://doi.org/10.1016/j.kisu.2017.09.001

KEYWORDS: chronic kidney disease; hyperkalemia; potassium; treatment

Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Hyperkalemia is encountered more frequently in current medical practices due to the increasing incidence and prevalence of common chronic diseases, such as diabetes and chronic kidney disease,¹ which (along with common treatment used for their treatment) disturb potassium homeostasis.² Hyperkalemia, usually defined as serum potassium concentrations greater than 5.0 to 5.5 mEq/l, is widely recognized as a direct and life-threatening complication, although questions remain about when and how to correct it.³ Hyperkalemia most often results from the failure of renal adaptation to potassium imbalance resulting from a combination of intrinsic and extrinsic factors.²,⁴,⁵ Intrinsic factors include decreased glomerular filtration rate, decreased distal delivery of sodium, selective reduction in distal tubule secretory function, impaired mineralocorticoid activity, and metabolic disturbances, such as acidemia and hyperglycemia. Common extrinsic factors are drugs that impair physiologic responses to hyperkalemia (e.g., various inhibitors of the renin-angiotensin-aldosterone system (RAAS), and potassium intake (e.g., a diet rich in potassium, or potassium supplements).⁴,⁶ The frequency of chronic hyperkalemia is increased in current medical practice in part because RAAS inhibitors have undisputed beneficial effects in patient groups that are most susceptible to the development of hyperkalemia; for example, patients with chronic kidney disease (CKD), diabetes mellitus, or congestive heart failure.¹ Because hyperkalemia hinders the use of these beneficial agents, and because hyperkalemia can be a life-threatening condition, there is a need to understand the complex causes of hyperkalemia and be aware of strategies to address the disorder in a way that provides the most optimal outcome for affected patients. More than 50 years after the clinical introduction of sodium polystyrene sulfonate as an ion-exchange resin to treat hyperkalemia,⁷–⁹ a new paradigm has emerged in the treatment of hyperkalemia, aided by the development of 2 new oral agents to reduce serum potassium levels.¹⁰,¹¹

Risk factors and outcomes of chronic hyperkalemia

Potassium is a critical participant in the bioelectricity generated by ion gradients and flows between the extracellular and intracellular compartments and thus essential to all vascular and neuromuscular excitation, contraction, and conduction.⁶,¹² Hyperkalemia therefore alters a critical gradient and impairs the function of excitable tissues, most notably cardiac. All cells possess the ubiquitous Na⁺-K⁺ ATPase, which
pumps Na⁺ out of, and K⁺ into the cell. This leads to a K⁺ gradient across the cell membrane (K⁺_{in} > K⁺_{out}), which is partially responsible for maintaining the potential difference across the membrane. This potential difference is important to the function of all cells, but is especially important in excitable tissues such as nerve and muscle. For these reasons, the body has developed numerous mechanisms for defense of normal serum K⁺. Total body K⁺ is approximately 50 mEq/kg, which in a 70-kg person would be approximately 3500 mEq. Most (98%) of this K⁺ is within cells, with only 2% in the extracellular fluid. The normal concentration of K⁺ in the extracellular fluid is 3.5 to 5.3 mEq/l. Large deviations from these values are not compatible with life.

Potassium homeostasis is maintained by several different mechanisms. As patients ingest approximately 100 mEq of potassium, the kidney is responsible for maintaining total body balance of potassium; however, the gastrointestinal (GI) tract also plays a small contributory role under normal circumstances. As patients lose kidney function, the GI tract takes over and plays a larger role in maintaining potassium balance. The normal kidney has a large capacity to excrete potassium and maintain a normal serum potassium concentration. To highlight this statement, we can turn to results of 5 studies conducted in patients with normal kidneys that placed these patients on a high-potassium diet (up to 400 mEq of potassium per day) and illustrated that the potassium serum concentrations stayed constant throughout the study (see Table 1). In the setting of high potassium intake, we accumulate potassium in the interstitial compartments of the kidney and the potassium can inhibit thick ascending limb sodium reabsorption, thereby providing more flow and sodium delivery to the downstream segments. However, it is unlikely that inhibiting sodium in this segment will have the fidelity needed to selectively modulate potassium transport and not cause overexcretion of sodium and water and resulting volume depletion. Given this fact, there is now an increased focus on the distal convoluted tubule as a more regionalized site by which dietary potassium intake may modulate potassium secretion. Recent evidence has identified the distal nephron as a K⁺ sensor whereby small changes in extracellular K⁺ concentration can lead to direct changes in the K⁺ secretory mechanism through alterations in activity of the with no lysine (WNK) family of kinases and their regulatory proteins SPAK and OxsR1. After a high dietary intake of potassium, subtle rises of potassium (even within the normal range) result in a slight polarization of the distal convoluted tubule cell leading to a higher intracellular chloride content. The WNK proteins are sensitive to changes in chloride content, resulting in an inhibitory effect on the thiazide-sensitive Na⁺-Cl⁻ cotransporter with an increase in sodium delivery to the more distal (aldosterone-sensitive) segments of the distal convoluted tubule and the collecting duct, increasing luminal electronegativity and providing luminal potassium secretion, and increasing luminal flow leading to enhanced potassium secretion through the Maxi-K channel. The distal nephron thus may possess an intrinsic potassium-sensing capacity to modulate potassium transport in a regionalized manner.

In addition to this potassium-sensing mechanism in the distal nephron, the ability to handle potassium loads might

---

**Table 1| Effect of prolonged K⁺ intake in healthy humans**

| Reference | Number of subjects | Method of increasing K⁺ intake | Baseline K⁺ intake (mEq/d) | Final K⁺ intake (mEq/d) | Duration of intervention (days) | Baseline serum K⁺ (mmol/l) | Final serum K⁺ (mmol/l) |
|-----------|--------------------|-------------------------------|----------------------------|------------------------|-------------------------------|---------------------------|--------------------------|
| Rabelink 1990 | 6                  | KCL supplement 300 mEq/d     | 100                        | 400                    | 20                            | 3.75                      | 4.22                     |
| Witzgall 1986 | 16                 | K citrate + KHCO₃ 2000       | 60                         | 260                    | 6                             | 4.2                       | 4.6                      |
| Sebastian 1994 | 6                  | KHCO₃ 120 mEq/d              | 59                         | 179                    | 18                            | 3.92                      | 4.15                     |
| Jenkins 2001 | 10                 | Grain-free vegetarian diet   | 98                         | 341                    | 14                            | 4.26                      | 4.03                     |
| Hene 1986    | 6                  | K citrate 220 mEq/d          | 80                         | 300                    | 14                            | 4.07                      | 4.48                     |
actually begin at the level of the stomach. When potassium enters into the stomach, it leads to rapid dephosphorylation of the Na\(^+\)-Cl\(^-\) cotransporter, allowing increased potassium secretion even though the blood potassium or mineralocorticoid levels have remained unchanged.\(^{29-31}\) This mechanism is highlighted in a recent study in which patients were placed on a mineralocorticoid blocker removing the effect of aldosterone, and then given a potassium load with a meal.\(^{32}\) Despite no change in the serum potassium level, there was a rapid increase in urinary excretion, supporting the presence of a gastric renal-sensing mechanism.

Normal potassium homeostasis is altered in CKD. In an animal model with 1 intact kidney and 1 kidney 50% removed, most potassium secretion initially originated in the intact kidney.\(^{33}\) After removing the intact kidney and leaving only the remnant kidney in place, there was a fourfold increase in potassium excretion within 1 day and a sixfold increase within 7 days,\(^{33}\) suggesting that in a patient with decreased nephron mass, the remaining nephrons undergo adaptive changes to enhance their potassium secretory capacity. This adaptation is mediated by enhanced sodium and flow through the remaining nephrons, with increased number and activity of the Na\(^+\)-K\(^+\) ATPase in the distal tubule.\(^{34,35}\) Although the adaptation to decreased nephron mass is quite profound and able to maintain potassium homeostasis under steady-state circumstances even with advanced CKD, the diseased kidney has much less capacity to handle acute potassium loads.\(^{36}\) This can be extrapolated to what we observe clinically where potassium excursions in patients with CKD are higher and more prolonged than in patients with normal renal function, and potentially leading to increased mortality. Such excursions can be even higher in patients with CKD who have additional exacerbating factors for hyperkalemia, such as receiving a RAAS inhibition blocker.

When evaluating the renal mechanisms of hyperkalemia, we should consider 3 causes: (i) primary decrease in mineralocorticoid activity; (ii) primary decrease in distal sodium delivery; and (iii) intrinsic abnormalities of the cortical collecting duct. Aldosterone interacts in the distal nephron and facilitates sodium reabsorption, and it enhances the luminal negative charge, which is a driving force for potassium secretion. Common causes of hyperkalemia include conditions impairing renin and aldosterone levels, such as diabetes, adrenal disease, numerous drugs (e.g., nonsteroidal anti-inflammatory drugs, beta blockers, renin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor blockers, amiloride, triamterene, cyclosporine, tacrolimus, heparin, ketoconazole, and trimethoprim), and elderly age (even if otherwise healthy). Despite age-related changes in potassium homeostasis, serum potassium is typically not elevated in elderly patients at baseline.\(^{37}\) However, slight perturbations in these homeostatic mechanisms can induce abrupt and life-threatening hyperkalemia. Another clinically relevant cause of hyperkalemia is the oral contraceptive drospirenone, which possesses anti-mineralocorticoid properties, and which has been associated with hyperkalemia when used in combination with RAAS inhibitors.\(^{3,38}\)

Hyperkalemia is regarded as a medical emergency due to its propensity to cause malignant arrhythmias.\(^{39,40}\) Indeed, hyperkalemia is associated with a substantial number of emergency department visits and hospital admissions.\(^{41}\) More importantly, hyperkalemia has been associated with increased short-term death rates in patients with and without CKD or end-stage renal disease,\(^{4,42-47}\) and with an increased risk of ventricular fibrillation.\(^{48}\) Most studies indicated that the potassium concentration associated with the best survival is approximately 4.0 to 4.5 mEq/l.\(^{42,44,47,48}\) Compounding the arrhythmogenic effects of hyperkalemia in patients with CKD and especially end-stage renal disease, there are various other exacerbating factors that frequently accompany abnormal potassium levels, such as hypocalcemia, hypomagnesemia, and metabolic alkalosis,\(^{39,50}\) and the presence of underlying comorbidities, such as left ventricular hypertrophy,\(^{51}\) which together may conspire to result in a very high risk of malignant arrhythmias in this population.

Besides its link to increased mortality and a heightened propensity for malignant arrhythmias, hyperkalemia is also able to cause other physiologic perturbations, such as muscle weakness and impaired renal acidification.\(^{52}\) Hyperkalemia suppresses proximal ammoniagenesis and the medullary transfer of ammonia leading to metabolic acidosis.\(^{55}\) This is especially important because metabolic acidosis may contribute to the progression of CKD\(^{56}\) and treatment of metabolic acidosis has been shown in small studies to slow progression of CKD.\(^{57,58}\) Besides its link to increased mortality and a heightened propensity for malignant arrhythmias, hyperkalemia is also able to cause other physiologic perturbations, such as muscle weakness and impaired renal acidification.\(^{54}\) Hyperkalemia suppresses proximal ammoniagenesis and the medullary transfer of ammonia leading to metabolic acidosis.\(^{55}\) This is especially important because metabolic acidosis contributes to the progression of CKD\(^{56}\) and treatment of metabolic acidosis has been shown to prevent progression of CKD.\(^{57,58}\)

### Therapies for chronic hyperkalemia in chronic kidney disease/ end-stage renal disease: something old, something new

The therapeutic approach to hyperkalemia consists of acute and chronic management. The goals of acute management are the prevention of life-threatening arrhythmias and the immediate lowering of serum potassium into safe ranges. The treatments used for acute management of hyperkalemia can be divided into 3 categories: (i) membrane stabilization through the administration of i.v. calcium; (ii) facilitation of potassium redistribution from extracellular to intracellular compartments by using insulin, beta-adrenergic agonists, and sodium bicarbonate (only if the pH is <7.2); and (iii) enhanced potassium elimination using diuretics, polystyrene sulfonate, or dialysis.\(^{60,61}\) A detailed discussion of acute hyperkalemia management is beyond the scope of this symposium, which is focused primarily on chronic hyperkalemia.
As discussed previously, there are several well-described risk factors for the development of chronic hyperkalemia, such as low glomerular filtration rate, diabetes, the use of RAAS blockage, and various other medications. A high-potassium diet can contribute, but only when there is also decreased ability to excrete potassium. Also, the major disease states that benefit from RAAS inhibition frequently coexist especially in older individuals with reduced glomerular filtration rate from aging or the cumulative effects of chronic diseases. Therefore, the nephrology community faces a paradoxical and clinically significant challenge because those patients who would benefit most from treatment with RAAS agents are those with the highest risk of adverse effects.

Randomized controlled clinical trials of RAAS inhibitors often implement systematic serum potassium monitoring and protocized interventions for hyperkalemia, and therefore offer valuable insight into the risks of hyperkalemia associated with RAAS inhibitor therapy and the efficacy of various intervention strategies to mitigate this complication. In the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) study, 1448 patients with type II diabetic kidney disease (stage 2–3) with albuminuria >300 mg/g on losartan 100 mg were randomly assigned to the addition of lisinopril or placebo to assess the effects on renal and safety endpoints. This study excluded patients with baseline serum potassium >5.5 mmol/l. On routine study laboratory testing, hyperkalemia (≥5.5 mmol/l) was observed in 18.4% of patients on losartan monotherapy and in 31.5% of those on combination therapy with lisinopril. Given how common hyperkalemia occurs in patients on RAAS blockade, the investigators developed a stepwise approach to managing hyperkalemia: (i) avoid interacting medications, (ii) low-potassium diet, and (iii) enhance excretion of potassium through the kidneys or the GI tract.

For mild hyperkalemia (potassium ≥5.0 mmol/l), the first step involved a review (and discontinuation, if feasible) of medications known to cause hyperkalemia, such as nonsteroidal anti-inflammatory drugs, and implementation of a low-potassium diet. A low-potassium diet is the mainstay of chronic hyperkalemia therapy; however, it does remove food items from the diet that are known to be healthy, such as fruits, vegetables, beans, nuts, and dairy. In everyday practice it may be difficult for patients to strictly maintain such a diet; it is thus important to provide proper education about how to substitute lower-potassium foods for the higher-potassium foods and to help them understand the importance of portion control. For example, high-potassium fruits, which include bananas, oranges, mango, apricots, and cantaloupe, can be substituted with one-half cup of apples, grapes, peaches, pears, and cranberries instead.

The next step in the VA NEPHRON-D for serum potassium >5.5 mmol/l was to add conservative treatment measures that enhance potassium excretion or potassium redistribution, such as the addition or enhanced dosing of diuretics if volume depletion was not a concern, chronic alkali therapy, liberalization of salt intake in select patients for whom volume status and hypertension was not a concern, and chronic low-dose sodium polystyrene sulfonate (15–30 g 3 times per week). For serum potassium >6.0 mmol/l the VA NEPHRON-D study required the withholding of RAAS inhibitor medications and the performance of an electrocardiogram. If there were no electrocardiogram changes typical of hyperkalemia and the serum potassium concentration was below 6.5 mmol/l, investigators administered 60 g sodium polystyrene sulfonate. If the serum potassium concentration was greater than 6.5 mmol/l or if there were electrocardiogram changes typical of hyperkalemia, then the investigators implemented the acute hyperkalemia protocol described previously.

For cases of severe hyperkalemia, especially in patients without kidney function, hemodialysis may be indicated to lower serum potassium. Furthermore, maintenance dialysis also ensures chronic potassium balance in patients with end-stage renal disease. In typical clinical practice, dialysis uses a dialysate potassium concentration that is lower than the serum potassium concentration, therefore creating a gradient across the semipermeable membrane that induces diffusive removal of potassium molecules from the body. Notwithstanding the importance of maintaining long-term potassium mass balance, the rapid dialytic removal of potassium typical of thrice-weekly hemodialysis regimens has raised concerns about the electrophysiologic consequences of rapid potassium shifts, especially in patients presenting with high predialysis serum potassium who are then dialyzed with low dialysate potassium baths. The Dialysis Outcomes and Practice Patterns Study (DOPPS) reported an increased risk of sudden death associated with low potassium dialysate compared with dialysate potassium ≥3.0 mmol/l, especially if predialysis potassium was greater than 5.0 mmol/l. However, a more recent DOPPS report found no association of low potassium dialysate with mortality and arrhythmia. Both high and low predialysis serum potassium levels were associated with increased mortality in this study, but after multivariable adjustments, only serum potassium >6.0 mmol/l was associated with increased mortality and arrhythmia. In another large study of patients with chronic maintenance hemodialysis, a mismatch between predialysis serum potassium and dialysate potassium (i.e., high predialysis serum potassium combined with higher ≥3.0 mmol/l) dialysate potassium, presumably resulting in inadequate dialytic removal and long-term accumulation of potassium) was also associated with higher risk of long-term mortality, underscoring the importance of potassium mass balance.

Recently, there has been a shift in chronic hyperkalemia treatment paradigms, centered on GI elimination using cation exchangers. The old mainstay cation exchanger used to treat hyperkalemia has been sodium or calcium polystyrene sulfonate (with or without sorbitol). Sodium polystyrene sulfonate was approved for the treatment of acute hyperkalemia in the United States in 1958, based on fairly weak experimental evidence. At the time of approval, the use...
of dialysis was not common and there were few to no alternative treatment options. One of the first studies of sodium polystyrene sulfonate was published in 1961 and evaluated a total of 32 patients. Of the patients included, 30 patients had oliguria, with 22 patients receiving oral and 8 patients receiving rectal sodium polystyrene sulfonate as an acute intervention; the remaining 2 patients received oral doses chronically. The mean decrease in serum potassium was 1 mmol/l. Although sodium polystyrene sulfonate is approved for the treatment of acute hyperkalemia, data on its efficacy and safety as a chronic therapy are very sparse. In a study of 33 patients with estimated glomerular filtration rate <40 ml/min per 1.73 m² and serum potassium 5.0 to 5.9 mmol/l, patients received either placebo or 30 g sodium polystyrene sulfonate daily for 7 days. Patients treated with sodium polystyrene sulfonate experienced a reduction in serum potassium of approximately 1 mmol/l, and experienced more frequent GI side effects. The lack of larger and longer-term randomized controlled clinical trials of sodium polystyrene sulfonate makes it difficult to systematically assess its safety profile. The most concerning risk of sodium polystyrene sulfonate is intestinal (colonic necrosis), which may be increased if administered with sorbitol or if there are other risk factors for intestinal adverse effects.69–73 The risk for colonic necrosis is estimated to be 0.27% to 1.8%, but the true incidence is not known and this agent should be used only in patients with normal bowel function. The more common adverse effects with sodium polystyrene sulfonate include GI side effects of constipation if used without sorbitol or diarrhea if used with sorbitol.73,75 There is also a theoretical risk of drug binding, but this has not been well studied.

Addressing the shortcomings of sodium polystyrene sulfonate, an emerging new treatment paradigm for management of chronic hyperkalemia centers around new oral agents: patiromer (RLY5016) and zirconium cyclosilicate (ZS-9). Patiromer is a nonabsorbed polymer-based binder that is formulated as a powder for oral suspension that binds potassium in the colon in exchange for calcium.74 Patiromer (Velvass) 8.4 g orally daily was approved by the US Food and Drug Administration for the management of nonemergent hyperkalemia in October 2015. This agent has an onset of action of 7 hours and a theoretical drug-binding risk, so the prescribing information suggests that it be separated by 3 hours from other medications. Based on in vitro studies, its binding capacity is about twice that of sodium polystyrene sulfonate.76 The OPAL-HK trial evaluated the short-term efficacy of patiromer in 237 patients with stage 3–4 CKD on RAAS inhibitors and with baseline serum potassium >5.0 and <6.5 mmol/l.77 There were 2 phases to the study: a 4-week single-group, single-blind study with treatment with patiromer and an 8-week, randomized, single-blind study. Overall, the potassium decreased from 5.6 to 4.6 mmol/l at week 4 with 76% of patients achieving the potassium target of <5.1 mmol/l. The 107 patients who achieved their target potassium in the initial short-term efficacy trial were randomized to the longer-term efficacy trial to receive patiromer or placebo for 8 weeks. Recurrence of hyperkalemia occurred in 60% of patients randomized to placebo compared with 15% of those randomized to patiromer (P < 0.001). In the 8-week phase 2, more individuals withdrawn from patiromer needed to stop RAAS inhibitors. The overall adverse event rates were similar between the treatment and placebo groups, with GI side effects seen more often in the patiromer group. The incidence of hypokalemia (serum potassium <3.0 mmol/l) was 5% and hypomagnesemia (serum magnesium <1.4 mg/dl) was 3%.77 Patiromer has been generally well tolerated when administered chronically over 52 weeks to 306 patients with diabetic nephropathy.78

Microporous zirconium cyclosilicate is an oral sorbent that is highly selective to trap potassium ions throughout the GI tract.79 Because of its high selectivity, zirconium cyclosilicate may bind potassium in the upper GI tract where the amount of potassium is high but the concentration is low.79 This agent is not currently approved in the United States, but recently received a positive opinion from the Europe Committee for Medicinal Products for Human Use. Zirconium cyclosilicate is being developed for the treatment of acute and chronic hyperkalemia. The HARMONIZE Study had an open-label acute treatment phase (10 g zirconium cyclosilicate thrice daily for 48 hours) in 258 patients with serum potassium ≥5.1 mmol/l and a second phase in those who achieved normal potassium in the first phase (92%), who were randomized to chronic treatment (placebo, and 5 g, 10 g, or 15 g per day of zirconium cyclosilicate).80 Zirconium cyclosilicate exerted its potassium-lowering effect relatively quickly, with a median time to potassium normalization of 2.2 hours, and showed a dose-response relationship in the chronic treatment phase. The overall adverse event rates were similar across the different groups, except for edema and hypokalemia and a suggestion of increased risk of urinary tract infections.80 In another randomized, double-blind, placebo-controlled clinical trial, 753 patients with serum potassium levels of 5.0 to 6.5 mmol/l were assigned to 3 different doses of zirconium cyclosilicate thrice daily for 48 hours versus placebo.79 Serum potassium decreased by a mean of 0.73 mmol/l in patients receiving 10 g zirconium cyclosilicate. After the initial 48 hours, 543 patients who achieved normokalemia were randomized to the original zirconium cyclosilicate dose administered once daily versus placebo, for 12 days. In this chronic phase, significantly more patients receiving 5 and 10 g zirconium cyclosilicate maintained normokalemia compared with placebo.79

Summary
In conclusion, hyperkalemia is an important electrolyte abnormality most often affecting patients with CKD, especially if combined with exacerbating factors, such as diabetes mellitus and treatment with RAAS inhibitors. Hyperkalemia is associated with higher mortality and with higher incidence of malignant arrhythmias, and also with metabolic abnormalities such as metabolic acidosis. The
serum potassium level that is associated with the lowest risk for adverse clinical outcomes is approximately 4 mmol/L.

Although every episode of hyperkalemia warrants clinical assessment, in the absence of systematic studies, a variety of clinical observations support the concept that mild hyperkalemia can be defined as serum potassium between 5.0 and 6.0 mmol/L and is generally amenable to outpatient management. Serum potassium levels above this range warrant more comprehensive assessment and may or may not be suitable for outpatient management. Electrocardiogram changes related to hyperkalemia are useful to determine the electrophysiologic relevance of the serum potassium level. The availability of newer, fully evaluated oral ion exchangers is likely to expand the opportunities for safe and effective outpatient management of hyperkalemia, and a wider application of RAAS inhibitors in patients with CKD and congestive heart failure. The long-term clinical effects of a strategy focusing on chronic potassium binder use in the face of RAAS inhibitor–induced hyperkalemia will need to be evaluated in future trials.

DISCLOSURE
Publication of this article was supported by AstraZeneca. LF has received speaking and consultant honoraria from Bayer and Sanofi, and research support from Abbvie. CPK has received speaking and consultant honoraria and advisory fees from Abbott, Abbvie, Amgen, AstraZeneca, Bayer, Fresenius Medical Care, Genzyme, Keryx, and Sanofi-Aventis; research support from Shire; travel support from Abbott, Abbvie, Amgen, Bayer, Keryx, Fresenius Medical Care, and Sanofi-Aventis; and NIH-NIDDK funding. BFP declared no competing interests.

ACKNOWLEDGMENTS
Publication of this article was supported by AstraZeneca. This supplement summarizes the two continuing medical education meetings held during the International Society of Nephrology/World Congress of Nephrology conference. The two educational meetings were supported by an educational grant from FibroGen and AstraZeneca. FibroGen and AstraZeneca had no involvement in the development of the two continuing medical education meetings or this supplement. The Med Ed Group, Inc, the meeting organizers, provided editorial support for this supplement. SynAptiv accredited the two continuing medical education meetings and has reviewed this supplement.

REFERENCES
1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.
2. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10:653–662.
3. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156–1162.
4. Palmer BF. Managing hyperkalaemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585–592.
5. Palmer BF. Hyperkalaemia in predialysis patients. Clin J Am Soc Nephrol. 2012;7:1201–1202.
6. Palmer BF, Clegg DJ. Achieving the benefits of a high-potassium, paleo diet, without the toxicity. Mayo Clin Proc. 2016;91:496–508.
7. Kayexalate: Sodium Polystyrene Sulfonate, USP Cation-Exchange Resin [Food and Drug Administration drug label]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; revised April 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011287s021lbl.pdf. Accessed June 27, 2017.
8. Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol: a preliminary report. N Engl J Med. 1961;264:111–115.
9. Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalaemia with a cation-exchange resin. N Engl J Med. 1961;264:115–119.
10. Kovesdy CP. Management of hyperkalaemia: an update for the internist. Am J Med. 2015;128:1281–1287.
11. Kovesdy CP. Updates in hyperkalaemia: outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18:41–47.
12. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050–1060.
13. Gunz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373:60–72.
14. Mathialahan T, MacLennan KA, Sandle LN, et al. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol. 2005;206:46–51.
15. Hayes CP Jr, Robinson RR. Fecal potassium excretion in patients on chronic intermittent hemodialysis. Trans Am Soc Artif Intern Organs. 1965;11:242–246.
16. Hayes CP Jr, McLeod ME, Robinson RR. An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207–216.
17. Palmer BF. A physiologic-based approach to the evaluation of a patient with hypokalemia. Am J Kidney Dis. 2010;56:1184–1190.
18. Hene RJ, Koorns AH, Boer P, et al. Adaptation to chronic potassium loading in normal man. Miner Electrolyte Metab. 1986;12:165–172.
19. Jenkins DJ, Kendall CW, Popovich DG, et al. Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function. Metabolism. 2001;50:494–503.
20. Rabelink TJ, Koorns AH, Hene RJ, et al. Early and late adjustment to potassium loading in humans. Kidney Int. 1990;38:942–947.
21. Sebastian A, Harris ST, Ottaway JH, et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med. 1994;330:1776–1781.
22. Witzgall H, Behr J. Effects of potassium loading in normal man on dopaminergic control of mineralocorticoids and renin release. J Hypertens. 1986;4:201–205.
23. Brandsch M, Keyes J, Windhager EE. Potassium-induced inhibition of proximal tubular fluid reabsorption in rats. Am J Physiol. 1972;222:421–427.
24. Stokes JB. Consequences of potassium recycling in the renal medulla. Effects of ion transport by the medullary thick ascending limb of Henle’s loop. J Clin Invest. 1962;40:219–229.
25. Suft CR, Jamison RL. Effect of acute potassium load on reabsorption in Henle’s loop in the rat. Am J Physiol. 1983;245:F569–F576.
26. Cheng CJ, Baum M, Huang CL. Kidney-specific WNK1 regulates sodium reabsorption and potassium secretion in mouse cortical collecting duct. Am J Physiol Renal Physiol. 2013;304:F397–F402.
27. Hadchouel J, Ellison DH, Gamba G. Regulation of renal electrolyte transport by WNK and SPAK-OSR1 kinases. Annu Rev Physiol. 2016;78:367–389.
28. Liu Z, Xie J, Wu T, et al. Overregulation of NCC and NKCC2 cotransporters by kidney-specific WNK1 revealed by gene disruption and transgenic mouse models. Hum Mol Genet. 2011;20:855–866.
29. Lee FH, Oh G, McDonough AA, et al. Evidence for gut factor in K+–homeostasis. Am J Physiol Renal Physiol. 2007;293:F541–F547.
30. Oh KS, Oh YT, Kim SW, et al. Gut sensing of dietary K(+)-intake increases renal K(+)-excretion. Am J Physiol Regul Integr Comp Physiol. 2011;301: R421–R429.
31. Youn JH. Gut sensing of potassium intake and its role in potassium homeostasis. Semin Nephrol. 2013;33:248–256.
32. Preston RA, Afshartous D, Rodco R, et al. Evidence for a gastrointestinal–renal kaluretic signaling axis in humans. Kidney Int. 2015;88:1383–1391.
33. Schultz RG, Taggart DD, Shapiro H, et al. On the adaptation in potassium excretion associated with nephron reduction in the dog. J Clin Invest. 1971;50:1061–1068.
34. Fine LG, Yanagawa N, Schultz RG, et al. Functional profile of the isolated uremic nephron: potassium adaptation in the rabbit cortical collecting tubule. J Clin Invest. 1979;64:1033–1043.
35. Stanton BA. Renal potassium transport: morphological and functional adaptations. Am J Physiol. 1989;257:R989–R997.
36. Bourgoignie JJ, Kaplan M, Pincus J, et al. Renal handling of potassium in dogs with chronic renal insufficiency. Kidney Int. 1981;20:482–490.
37. Mullerin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol. 1995;6:1459–1462.
38. Bird ST, Pepe SR, Etminan M, et al. The association between drosopirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol. 2011;11:23.
39. Epstein FH. Signs and symptoms of electrolyte disorders. In: Maxwell MH, Kleeman CR, eds. Clinical Disorders of Fluid and Electrolyte Metabolism. 3rd ed. New York: McGraw-Hill, 1980:499–516.
40. Fisch C. Electrolytes and the heart. In: Hurst JW, ed. The Heart. New York: McGraw-Hill, 1982:1599.
41. US Dept of Health and Human Services, Agency for HealthCare Research and Quality. Web site. Available at: http://hcpnet/ahrq.gov. Accessed December 21, 2015.
42. Hayes J, Kalantar-Zadeh K, Lu JL, et al. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012;120:c8–c16.
43. Korgaonkar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010;5:762–769.
44. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46:213–221.
45. Lownie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482.
46. Ikemi K, Uehara H, Nishime K, et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis. 1996;28:541–548.
47. Kovacs CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2:999–1007.
48. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157–164.
49. Yetkin E, Ileri M, Tandogan I, et al. Increased QT interval dispersion after hemodialysis: role of peridialytic electrolyte gradients. Angiology. 2000;51:499–504.
50. Nappi SE, Virtanen VK, Saha HH, et al. QTc dispersion increases during hemodialysis with low-calcium dialysate. Am J Nephrol. 2013;41:217–222.
51. Burton JO, Korsheed S, Grundy BJ, et al. Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. Ren Fail. 2008;30:701–709.
52. Voroneanu L, Covic A. Arrhythmias in hemodialysis patients. J Nephrol. 2009;22:716–725.
53. Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial. 2007;20:220–228.
54. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347:93–100.
55. Dubose TD Jr. Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. Kidney Int. 1997;51:591–602.
56. Kovacs CP. Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant. 2012;27:3056–3062.
57. de Brito-Ashurst J, Varagunam M, Rafferty MJ, et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–2084.
58. Goraya N, Simon J, Co J, et al. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int. 2012;81:86–93.
59. Rossignol P, Legrand M, Kosiaboro M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113:585–591.
60. Allon M, Copney C. Albuteol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1999;58:869–872.
61. Blumberg A, Weidmann P, Shaw S, et al. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85:507–512.
62. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–1903.
63. Marques JS, Diogo AN. Dead man walking: an extreme case of sinusoidal wave pattern in severe hyperkalemia. J Am Coll Cardiol. 2012;59:2118–2126.
64. Petrov DB. Images in clinical medicine. An electrocardiographic sine wave in hyperkalemia. N Engl J Med. 2012;366:1824.
65. Siniorakis E, Arvanitakis S, Psatheris G, et al. Hyperkalaemia, pseudohy perkalaemia and electrocardiographic correlates. Int J Cardiol. 2011;148:242–243.
66. Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2012;7:765–774.
67. Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2017;69:266–277.
68. Lepage L, Dufour AC, Doinor J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10:2136–2142.
69. Chelcun JL, Sable RA, Friedman K. Colonic ulceration in a patient with renal disease and hyperkalemia. JAAAPA. 2012;25:34, 37–38.
70. Gorospe EC, Lewis JT, Bruining DH. Kayexalate-induced esophageal ulcer in a patient with gastroparesis. Clin Gastroenterol Hepatol. 2012;10:A28.
71. Joo M, Bae WK, Kim NH, et al. Colonic mucosal necrosis following administration of calcium polystyrene sulfonate (Kalimite) in a uremic patient. J Korean Med Sci. 2009;24:1207–1211.
72. Takeuchi N, Nomura Y, Mada T, et al. Development of colonic perforation during calcium polystyrene sulfonate administration: a case report. Case Rep Med. 2013;2013:102614.
73. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126:264.e9–e24.
74. Gerstman BB, Kirkman R, Plarr R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis. 1992;20:159–161.
75. Sterns RH, Rojas M, Bernstein P, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21:733–735.
76. Chaitman M, D doit D, Bridgeman MB. Potassium-binding agents for the clinical management of hyperkalemia. P T. 2016;41:43–50.
77. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211–221.
78. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314:151–161.
79. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222–231.
80. Kosiaboro M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312:2223–2233.